A Phase 1 interventional study of Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) and Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin) in Bacterial Vaginosis, sponsored by Danylo Halytsky Lviv National Medical University. Active, not recruiting at 1 site in Ukraine. Open to female participants aged 15 Years to 49 Years. Per ClinicalTrials.gov, last updated 2024-09-27.
Sponsored by Danylo Halytsky Lviv National Medical University · Phase 1, Interventional, and Diagnostic
Research concerning women pathogenic microflora during different conditions
Study of microflora of different groups of women of reproductive age, determination of pathogens and their further study, samples of a newly synthesized compound on isolated pathogens
220 studies on the registry are indexed under Vaginosis, Bacterial; 36 are open to participants now.
This study's planned enrollment of 200 is above the median of 100 across 187 interventional studies indexed under Vaginosis, Bacterial.
Browse Vaginosis, Bacterial studies →This is the only study on the registry with Danylo Halytsky Lviv National Medical University as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Women with bacterial vaginosis (symptomatic or asymptomatic)
Diagnostic Test: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) · Drug: Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin) · Combination Product: Suppositoria for vaginal microflora recovery (Giynoflor) · Drug: Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)
Pregnant women with different ifections
Diagnostic Test: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) · Drug: Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin) · Combination Product: Suppositoria for vaginal microflora recovery (Giynoflor) · Drug: Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)
Women with asymptomic infections of urogenital tract
Diagnostic Test: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) · Drug: Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin) · Combination Product: Suppositoria for vaginal microflora recovery (Giynoflor)
Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features
Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.
Prescription of antifungal drugs. Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most
Estimation of the immune activity
Detection of quantities of different immune cells: lymphocytes, leukocytes, neutrophils, eosinophils
Time frame: 1 month
Quantities of vaginal microflore bacteria
Detection of quantities of vaginal microflore bacteria before and after antibiotic therapy (in TBC)
Time frame: 2 months
Quantities of bacteria in urine
Detection of quantities of bacteria in urine (in TBC)
Time frame: 2 months
Plan to share: No
This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.